about
Rickettsia monacensis as cause of Mediterranean spotted fever-like illness, ItalyCytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.Activation of MSRV-type endogenous retroviruses during infectious mononucleosis and Epstein-Barr virus latency: the missing link with multiple sclerosis?Complications in treating chronic hepatitis B in patients with HIV.Hepatic peroxisome proliferator-activated receptor γ and α-mRNA expression in HCV-infected adults is decreased by HIV co-infection and is also affected by ethnicity.Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy.The changing face of the HIV epidemic in Northern Sardinia: increased diagnoses among pregnant women.Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.Ebola virus disease: Case management in the Institute of Infectious Diseases, University Hospital of Sassari, Sardinia, Italy.Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era.Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients.Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients.Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype.Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes.Very late HCV relapse following triple therapy for hepatitis C.Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings.Mucocutaneous leishmaniasis as presentation of HIV infection in Sardinia, insular Italy.Serum homocysteine levels are increased in women with gestational diabetes mellitus.Kaposi's sarcoma herpes virus and Kaposi's sarcoma in the elderly populations of 3 Mediterranean islands.Factors influencing hospital infection control policies in Italian hospitals.Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.Modulation by α- and γ-tocopherol and oxidized low-density lipoprotein of apoptotic signaling in human coronary smooth muscle cells∗Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral DrugsEpisodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcomeDoes counseling increase sustained benefit of HAART among prison inmates after release to the community?Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in ItalyAutoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis CFirst HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome
P50
Q24612669-9D9B4533-90CE-4C4A-9708-691E34934A1DQ33415344-8881CBBD-4733-471A-80FB-9828570659FBQ35043515-2B6FB865-0848-4976-BCD2-28A2F56659E8Q36327100-EFAAA9AB-9A57-4128-95EE-4B44F2E1DEB0Q36364689-A87B5DC0-54F3-41D5-A2E2-F4B6A1F333E1Q36702110-89380150-4A01-4839-82AA-556C615035E1Q38876960-E5312D50-2C5E-4A63-8675-661EB243A10FQ38932602-DFD12ED3-0D2E-49A7-8CEC-690D4028B514Q39127382-92C4325E-5FB3-40C2-9E2F-FE86715B121BQ39201771-F9888540-EBC6-4B6F-9893-AD51EC150AFDQ39295258-E3347AFE-F519-4076-88DE-DDC1AE4A28BAQ40103230-FF470C88-7E4F-4B65-94FE-360F377A8A63Q42978278-6E5D1081-58FA-4CE4-85AE-F31E3F79353BQ42978496-C8CE8843-1A4A-4460-AEB5-2A75375B39AAQ42985177-84D9EC00-EF5A-4F6F-8275-FE4649C62C94Q42994898-C48CF0C1-1CB3-40C1-9D2E-AF2F71A5C628Q42998292-A80F0853-F586-4967-BCF5-C18F6FF53E75Q43000220-A1DB33FC-0679-4346-9F55-F93A7B9CD7F4Q43124515-B13A5570-0470-46EF-A9F4-32D4523564DCQ44026224-648E4A97-201D-48E3-9CE3-9BDC09A1735DQ44473922-BB8C42E1-B444-4BFA-BB58-71B56B53F567Q45738236-463B91A0-8B18-49A6-9CD2-D635AAF34952Q50716696-207B78D3-653F-48ED-BE3C-5F1317D3D9D8Q51499682-B4BE7043-D58E-4E35-A15B-44C06E3B62DEQ58863676-E50A2861-F7D7-4866-B045-5DC8D7043C2EQ59240888-48EB1F0C-25CF-465D-874C-5D0F148186B8Q80487136-F17CD4C7-8364-445B-8B8F-C567BAE46584Q81285711-852D9C87-9A8B-4FF1-88BE-E533C3505397Q81761298-806B4980-1C2D-428A-814D-3FA5056C703CQ82209330-EEA4867F-5B3F-4B92-8020-27D8379D3FDAQ84566621-FB8AD54B-5E84-4EF6-8114-AA1116E18FA4
P50
description
researcher ORCID ID = 0000-0003-4895-7576
@en
wetenschapper
@nl
name
Ivana Maida
@ast
Ivana Maida
@en
Ivana Maida
@es
Ivana Maida
@nl
type
label
Ivana Maida
@ast
Ivana Maida
@en
Ivana Maida
@es
Ivana Maida
@nl
prefLabel
Ivana Maida
@ast
Ivana Maida
@en
Ivana Maida
@es
Ivana Maida
@nl
P1153
57192331825
P31
P496
0000-0003-4895-7576